{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:34:22Z","timestamp":1778852062709,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jcv.2015.08.015","type":"journal-article","created":{"date-parts":[[2015,9,13]],"date-time":"2015-09-13T02:08:20Z","timestamp":1442110100000},"page":"114-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Development and persistence of DAA resistance associated mutations in patients failing HCV treatment"],"prefix":"10.1016","volume":"72","author":[{"given":"Stefania","family":"Paolucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta","family":"Fiorina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Landini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Gulminetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Novati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Maserati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Barbarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Baldanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2015.08.015_bib0005","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.08.015_bib0010","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jcv.2015.08.015_bib0015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2036.2012.04992.x","article-title":"UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients","volume":"35","author":"Ramachandran","year":"2012","journal-title":"Alim. Pharmacol. Ther."},{"key":"10.1016\/j.jcv.2015.08.015_bib0020","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.08.015_bib0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.08.015_bib0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/liv.12693","article-title":"Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a phase 2b study","volume":"35","author":"Zeuzem","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.jcv.2015.08.015_bib0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2011.08.015","article-title":"Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir","volume":"52","author":"Susser","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.08.015_bib0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/jvh.12230","article-title":"Importance of HCV genotype 1 subtypes for drug resistance and response to therapy","volume":"21","author":"Wyles","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.jcv.2015.08.015_bib0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1743-422X-9-245","article-title":"Naturally occurring mutations to HCV protease inhibitors in treatment-na\u00efve patients","volume":"9","author":"Paolucci","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.jcv.2015.08.015_bib0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","article-title":"Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na\u00efve patients","volume":"10","author":"Paolucci","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.jcv.2015.08.015_bib0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jviromet.2012.05.006","article-title":"Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV","volume":"184","author":"Fiorina","year":"2012","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2015.08.015_bib0060","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/135965350801300413","article-title":"Mapping natural polymorphisms of hepatitis C virus NS3\/4A protease and antiviral resistance to inhibitors in worldwide isolates","volume":"13","author":"L\u00f3pez-Labrador","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2015.08.015_bib0065","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.08.015_bib0070","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.25962","article-title":"Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial","volume":"56","author":"De Meyer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.08.015_bib0075","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with hepatitis C virus infection to boceprevir","volume":"143","author":"Poordad","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2015.08.015_bib0080","doi-asserted-by":"crossref","first-page":"e34372","DOI":"10.1371\/journal.pone.0034372","article-title":"Hepatitis C viral evolution in genotype 1 treatment-na\u00efve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials","volume":"7","author":"Kieffer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2015.08.015_bib0085","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2015.08.015_bib0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2015.08.015_bib0095","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2015.08.015_bib0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.antiviral.2007.11.010","article-title":"Characterization of resistance mutations against HCV ketoamide protease inhibitors","volume":"77","author":"Tong","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jcv.2015.08.015_bib0105","first-page":"139","article-title":"Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection","volume":"20","author":"Wyles","year":"2012","journal-title":"Top Antivir. Med."},{"key":"10.1016\/j.jcv.2015.08.015_bib0110","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/AAC.05166-11","article-title":"In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335","volume":"56","author":"Lagac\u00e9","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.08.015_bib0115","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1128\/AAC.00822-13","article-title":"Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study","volume":"57","author":"Berger","year":"2013","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215006502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215006502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T19:08:58Z","timestamp":1653160138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653215006502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":23,"alternative-id":["S1386653215006502"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2015.08.015","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and persistence of DAA resistance associated mutations in patients failing HCV treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2015.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}